GLSI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers...

Stats
Šios dienos apimtis	27 889.00
Vidutinė apimtis	52 203.00
Rinkos kapitalizacija	168.96M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $-0.200 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.01
ATR14	$0.170 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Snehal	Buy	3 000	Common Stock
2024-03-22	Patel Snehal	Buy	2 500	Common Stock
2024-03-20	Patel Snehal	Buy	1 500	Common Stock
2024-03-05	Patel Snehal	Buy	30 500	Common Stock
2024-03-04	Patel Snehal	Buy	4 100	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 968 139 \| Sell: 271 338

Greenwich LifeSciences, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Greenwich LifeSciences, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2023
Pajamos:	$0
Bruto pelnas:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2022
Pajamos:	$0
Bruto pelnas:	$-3 612.00 (0.00 %)
EPS:	$-0.590

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Greenwich LifeSciences,

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.